Innovent Biologics, Inc. has announced a strategic partnership with WeComput. This collaboration aims to enhance Innovent’s AI for Drug Discovery platform.
Innovent is a biopharmaceutical company that develops medicines for oncology, cardiovascular, autoimmune, and other major diseases. By combining their technologies, Innovent and WeComput aim to accelerate drug discovery and development through AI.
Innovent Academy, an R&D engine of Innovent, will use WeComput’s WeMol, a molecular design platform, to improve its computing infrastructure and accelerate its drug research and development. WeMol will integrate NVIDIA’s BioNeMo to expand Innovent’s AI computing capabilities. This integration will enhance computational efficiency and streamline the drug discovery process.
The collaboration aims to create an efficient, user-friendly, and automated AI-driven drug discovery system. This will reduce Innovent’s AI implementation and experimental costs. It will also shorten the drug R&D cycle and improve the success rate.
Dr. Kaijie He, Vice President of Oncology Biology, said, “AI is injecting new momentum into the global pharmaceutical and biotech industries. We are excited to partner with WeComput and integrate advanced AI technology to boost our R&D capabilities and expedite the discovery and development of innovative drugs. We believe this collaboration will offer robust technical support to our research team, propelling us toward greater breakthroughs in the global pharmaceutical market.”
Harry (Hu) Ge, CEO of WeComput, stated, “This collaboration will be mutually beneficial, fostering the widespread application of AI technology in the biopharmaceutical sector and driving innovation and development in the global pharmaceutical industry.”
